Skip to content

BCBS Louisiana

Does BCBS Louisiana cover Wegovy?

No. BCBS Louisiana's policies on file exclude Wegovy for weight loss on Employer and ACA Marketplace plans.

Policy document

  • Bcbs Louisiana Wegovy 2026 08 01

    BCBS Louisiana · PA policy · Employer and ACA Marketplace

    Effective August 1, 2026. Verified September 23, 2026.

    View PDF Download Original insurer source
  • Employer and ACA Marketplace: Not covered. Policy 00886, effective August 1, 2026, page 11: the weight-loss exclusion applies to members whose contrac...

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Not covered

Policy 00886, effective August 1, 2026, page 11: the weight-loss exclusion applies to members whose contract excludes medications for obesity, weight loss, weight management, or weight maintenance. The policy states that most member contracts exclude this benefit. Page 18 limits the policy approval criteria to cardiovascular risk reduction and MASH; no weight-loss approval checklist is established for contracts with weight-loss benefits.

Policy note: Codex source review on 2026-09-23 of the official August 1, 2026 policy, pages 1, 11, 18 and 21. Weight-loss scope only; the source does not establish BMI gates, approval durations, or documentation requirements for weight-loss benefits. A scheduled review date is not an expiration date. Cardiovascular and MASH entries on source document 220 are outside this publication.

Policy effective August 1, 2026 · verified September 23, 2026 · source: Bcbs Louisiana Wegovy 2026 08 01 · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial Authorization - CV Risk Reduction (Wegovy injection or tablet)

All of:

  • Patient is 45 years of age or older (ages 18-44 denied as not medically necessary; age <18 denied as investigational)
  • BMI ≥ 27 kg/m2 (BMI 25 to <27 denied as not medically necessary; BMI <25 denied as investigational)
  • Patient does NOT have Type I or Type II Diabetes Mellitus diagnosis AND does not have HbA1c ≥ 6.5%
  • Patient does NOT have NYHA Class IV heart failure, chronic pancreatitis, or acute pancreatitis within the last 180 days
  • Patient does NOT have personal history of, or first-degree relative with, medullary thyroid carcinoma or personal history of MEN 2
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Patient will NOT use medication in combination with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists
  • Patient will use medication in combination with guideline-directed pharmacotherapy for CVD (antiplatelet agent, lipid-lowering drug, and antihypertensive therapy)

Plus any one of:

  • Prior myocardial infarction (MI)
  • Prior stroke (ischemic or hemorrhagic) or documented history of TIA
  • Angina pectoris with significant atherosclerosis (≥ 50% stenosis)
  • Prior PTCA or CABG
  • Symptomatic carotid stenosis (≥ 50% stenosis)
  • Prior carotid endarterectomy or carotid artery angioplasty and stenting
  • Aortic aneurysm secondary to atherosclerosis or history of aortic aneurysm repair
  • Symptomatic PAD evidenced by: intermittent claudication with ABI <0.85 (at rest), OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease

Continuation Authorization - CV Risk Reduction (Wegovy injection)

All of:

  • Patient has received an initial authorization for Wegovy injection or tablets
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Patient had a BMI ≥ 27 kg/m2 prior to initiation of therapy (BMI 25 to <27 at initiation denied as not medically necessary; BMI <25 at initiation denied as investigational)
  • Patient has NOT developed Type II DM since the previous authorization
  • Patient does NOT have NYHA Class IV heart failure, chronic pancreatitis, or acute pancreatitis within the last 180 days
  • Patient will continue guideline-directed pharmacotherapy for CVD (antiplatelet agent, lipid-lowering drug, and antihypertensive therapy)
  • Patient is tolerating a Wegovy injection maintenance dose of 2.4 mg once weekly
  • Patient will NOT use medication in combination with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists

Plus any one of:

  • Prior MI
  • Prior stroke (ischemic or hemorrhagic) or documented history of TIA
  • Angina pectoris with significant atherosclerosis (≥ 50% stenosis)
  • Prior PTCA or CABG
  • Symptomatic carotid stenosis (≥ 50% stenosis)
  • Prior carotid endarterectomy or carotid artery angioplasty and stenting
  • Aortic aneurysm secondary to atherosclerosis or history of aortic aneurysm repair
  • Symptomatic PAD evidenced by: intermittent claudication with ABI <0.85 (at rest), OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease

Continuation Authorization - CV Risk Reduction (Wegovy tablet)

All of:

  • Patient has received an initial authorization for Wegovy injection or tablets
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Patient had a BMI ≥ 27 kg/m2 prior to initiation of therapy (BMI 25 to <27 at initiation denied as not medically necessary; BMI <25 at initiation denied as investigational)
  • Patient has NOT developed Type II DM since the previous authorization
  • Patient does NOT have NYHA Class IV heart failure, chronic pancreatitis, or acute pancreatitis within the last 180 days
  • Patient will continue guideline-directed pharmacotherapy for CVD (antiplatelet agent, lipid-lowering drug, and antihypertensive therapy)
  • Patient is tolerating a Wegovy tablet maintenance dose of 25 mg once daily
  • Patient will NOT use medication in combination with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists

Plus any one of:

  • Prior MI
  • Prior stroke (ischemic or hemorrhagic) or documented history of TIA
  • Angina pectoris with significant atherosclerosis (≥ 50% stenosis)
  • Prior PTCA or CABG
  • Symptomatic carotid stenosis (≥ 50% stenosis)
  • Prior carotid endarterectomy or carotid artery angioplasty and stenting
  • Aortic aneurysm secondary to atherosclerosis or history of aortic aneurysm repair
  • Symptomatic PAD evidenced by: intermittent claudication with ABI <0.85 (at rest), OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of patient age ≥ 45 years
  • Baseline BMI documentation ≥ 27 kg/m2
  • Documentation of established CVD qualifying event (prior MI, prior stroke/TIA, angina with ≥ 50% stenosis, prior PTCA/CABG, symptomatic carotid stenosis ≥ 50%, prior carotid endarterectomy/stenting, aortic aneurysm, or symptomatic PAD with ABI <0.85/revascularization/amputation)
  • Documentation confirming no diagnosis of Type I or Type II Diabetes Mellitus
  • HbA1c lab result confirming HbA1c < 6.5%
  • Documentation of current guideline-directed pharmacotherapy for CVD (antiplatelet agent, lipid-lowering drug, and antihypertensive therapy) or clinical justification if any component is not used
  • Documentation confirming no NYHA Class IV heart failure diagnosis
  • Documentation confirming no chronic pancreatitis and no acute pancreatitis within the last 180 days
  • Documentation confirming no personal history or first-degree family history of medullary thyroid carcinoma or MEN 2
  • Prescriber attestation that medication will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Prescriber attestation that medication will NOT be used in combination with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists
  • For continuation (injection): Documentation that patient is tolerating Wegovy injection maintenance dose of 2.4 mg once weekly
  • For continuation (tablet): Documentation that patient is tolerating Wegovy tablet maintenance dose of 25 mg once daily
  • For continuation: Documentation confirming patient has not developed Type II DM since previous authorization

Approval and renewal

  • Initial approval: 6 months
  • Renewal: For continuation: patient must have established CVD (same qualifying events as initial), must have had a baseline BMI ≥ 27 kg/m2 prior to therapy initiation, must not have developed Type II DM since previous authorization, must not have NYHA Class IV heart failure/chronic pancreatitis/acute pancreatitis within last 180 days, must continue GDMT, and must be tolerating maintenance dose (2.4 mg/week for injection or 25 mg/day for tablet). Age ≥ 45 is NOT re-verified at continuation. A1C exclusion (≥6.5%) is NOT explicitly re-verified at continuation (only new T2DM diagnosis is checked).
  • Renewal: Staying on a maintenance dose of at least 2.4 mg.

Not covered when

  • Type II Diabetes Mellitus diagnosis
  • HbA1c ≥ 6.5%
  • NYHA Class IV heart failure
  • Chronic pancreatitis
  • Acute pancreatitis within the last 180 days
  • Personal history of medullary thyroid carcinoma
  • First-degree relative with medullary thyroid carcinoma
  • Personal history of Multiple Endocrine Neoplasia type 2 (MEN 2)
  • Concomitant use with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists
  • Age < 18 (investigational)
  • Age 18-44 (denied as not medically necessary)
  • BMI < 25 (investigational)
  • BMI 25 to <27 (denied as not medically necessary)
  • Use without concomitant behavioral modification and reduced-calorie diet (investigational)
  • No established cardiovascular disease (not covered for contracts excluding obesity medications; not medically necessary for contracts including obesity medications)
  • Type 1 diabetes

Policy note: Policy covers both Wegovy injection and Wegovy tablet for CV risk reduction. Initial authorization is for 6 months. For contracts that INCLUDE obesity medication coverage, the established CVD requirement and GDMT requirement are additional company requirements (denial as not medically necessary if not met). For contracts that EXCLUDE obesity medication coverage, lack of established CVD results in a not covered determination. Wegovy tablet lacks a dedicated CV outcomes trial; support for this indication is based on pharmacokinetic modeling. The policy explicitly excludes patients with T1DM or T2DM AND HbA1c ≥ 6.5% (considered investigational). Ages 18-44 are denied as not medically necessary (not investigational). Minimum maintenance dose for continuation of injection is 2.4 mg/week; for tablet is 25 mg/day.

Policy effective May 1, 2026 · verified June 2, 2026 · source: 00886%2020240812%20 Wegovy%20semaglutideaccessible%20pdf

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial Authorization - MASH (Wegovy injection only)

All of:

  • Patient is 18 years of age or older
  • Confirmed and documented diagnosis of MASH with moderate to advanced liver fibrosis (stages F2 to F3) - NOT cirrhosis (F4) and NOT hepatic decompensation
  • Patient does NOT have cirrhosis (F4) or hepatic decompensation
  • Patient does NOT have Type I Diabetes Mellitus diagnosis
  • Patient does NOT have acute pancreatitis within the last 180 days
  • Patient has no history or current evidence of chronic pancreatitis
  • Patient does NOT have documented causes of chronic liver disease other than MASLD
  • Patient has no history or current evidence of hepatocellular carcinoma
  • Patient does NOT have personal history of, or first-degree relative with, medullary thyroid carcinoma or personal history of MEN 2
  • Patient does NOT have excessive alcohol use within past 3 months (defined as >20 g/day for women and >30 g/day for men)
  • Patient's concomitant related conditions (dyslipidemia, Type II diabetes, hypertension) are managed according to standard of care
  • Medication will be used in conjunction with lifestyle interventions (diet and exercise)
  • Patient will NOT use medication in combination with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists
  • Patient will NOT use medication in combination with Rezdiffra (resmetirom tablets)

Plus any one of:

  • Liver biopsy within the last 12 months confirming MASH with F2-F3 fibrosis AND (if biopsy used) NAFLD Activity Score (NAS) ≥ 4 with score > 1 in ALL of: steatosis, hepatocyte ballooning, and lobular inflammation
  • Imaging-based elastography within the last 6 months confirming F2-F3 fibrosis (vibration-controlled elastography/FibroScan, transient elastography, shear wave elastography, or magnetic resonance elastography)

Continuation Authorization - MASH (Wegovy injection only)

All of:

  • Patient has an initial authorization for the requested medication
  • Patient has documentation of a diagnosis of MASH with moderate to advanced liver fibrosis (stages F2 to F3)
  • Patient has NOT progressed to stage F4 (cirrhosis)
  • Patient has been adherent to treatment with Wegovy
  • Patient is experiencing a positive clinical response (stabilization and/or improvement in fibrosis and/or MASH)
  • Patient's concomitant related conditions (dyslipidemia, Type II diabetes, hypertension) are managed according to standard of care
  • Patient does NOT have excessive alcohol use within past 3 months (>20 g/day for women and >30 g/day for men)
  • Patient is tolerating a maintenance dose of 2.4 mg once weekly
  • Patient will NOT use medication in combination with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists
  • Patient will NOT use medication in combination with Rezdiffra (resmetirom tablets)

Documentation to bring

  • Documentation of patient age ≥ 18 years
  • Confirmed and documented diagnosis of MASH with moderate to advanced liver fibrosis (F2 to F3 fibrosis)
  • Liver biopsy report within the last 12 months confirming MASH with F2-F3 fibrosis (if biopsy used as confirmation method), OR imaging-based elastography report within the last 6 months (FibroScan/VCTE, transient elastography, shear wave elastography, or MRE) confirming F2-F3 fibrosis
  • If liver biopsy used: NAFLD Activity Score (NAS) ≥ 4 documented, with score > 1 in ALL of steatosis, hepatocyte ballooning, and lobular inflammation
  • Documentation confirming no cirrhosis (F4) or hepatic decompensation
  • Documentation confirming no Type I Diabetes Mellitus diagnosis
  • Documentation confirming no acute pancreatitis within the last 180 days
  • Documentation confirming no history or current evidence of chronic pancreatitis
  • Documentation confirming no other documented causes of chronic liver disease other than MASLD
  • Documentation confirming no history or current evidence of hepatocellular carcinoma
  • Documentation confirming no personal history or first-degree family history of medullary thyroid carcinoma or MEN 2
  • Documentation confirming patient does not have excessive alcohol use within past 3 months (>20 g/day women, >30 g/day men)
  • Documentation that comorbid conditions (dyslipidemia, T2DM if present, hypertension) are managed per standard of care
  • Prescriber attestation that medication will be used in conjunction with lifestyle interventions (diet and exercise)
  • Prescriber attestation that medication will NOT be used in combination with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists
  • Prescriber attestation that medication will NOT be used in combination with Rezdiffra (resmetirom tablets)
  • For continuation: Documentation of positive clinical response (stabilization and/or improvement in fibrosis and/or MASH)
  • For continuation: Documentation confirming adherence to treatment
  • For continuation: Documentation that patient is tolerating maintenance dose of 2.4 mg once weekly
  • For continuation: Documentation confirming patient has not progressed to F4 cirrhosis

Approval and renewal

  • Renewal: For continuation: patient must be experiencing a positive clinical response as evidenced by documentation of stabilization and/or improvement in fibrosis and/or MASH (e.g., improved steatosis, improved fibrosis, improvement in fibrosis score, lack of disease progression). Patient must not have progressed to stage F4 (cirrhosis). Patient must have been adherent to treatment. Patient must be tolerating maintenance dose of 2.4 mg once weekly. Comorbid conditions (dyslipidemia, T2DM, hypertension) must be managed per standard of care. Alcohol limits continue to apply (within past 3 months). Initial diagnosis confirmation testing (biopsy/imaging) is NOT re-required at continuation — only documentation of MASH F2-F3 diagnosis is needed.
  • Renewal: Staying on a maintenance dose of at least 2.4 mg.

Not covered when

  • Cirrhosis (F4) or hepatic decompensation (investigational for contracts including obesity medications; not covered for contracts excluding obesity medications)
  • Acute pancreatitis within the last 180 days
  • History or current evidence of chronic pancreatitis
  • Documented causes of chronic liver disease other than MASLD
  • History or current evidence of hepatocellular carcinoma
  • Personal history of medullary thyroid carcinoma
  • First-degree relative with medullary thyroid carcinoma
  • Personal history of MEN 2
  • Excessive alcohol use within past 3 months (>20 g/day for women or >30 g/day for men)
  • Concomitant use with Rezdiffra (resmetirom tablets) - investigational
  • Concomitant use with other GLP-1 Agonists or GLP-1/GIP Receptor Agonists - investigational
  • Wegovy TABLET formulation for MASH - explicitly not covered
  • Pediatric patients (age < 18) - investigational
  • Use without lifestyle interventions (diet and exercise) - investigational
  • Absence of confirmed MASH F2-F3 diagnosis (investigational for contracts including obesity medications; not covered for contracts excluding obesity medications)
  • Type 1 diabetes

Policy note: IMPORTANT: Only Wegovy injection is covered for MASH. Wegovy tablet for MASH is explicitly stated as not covered. The policy requires fibrosis staging F2 to F3 only — F1 and below are not covered, and F4 (cirrhosis) is explicitly excluded. Confirmation requires either liver biopsy within 12 months OR imaging-based elastography (specifically: FibroScan/VCTE, transient elastography, shear wave elastography, or MRE) within 6 months. Note that FIB-4 and ELF (serum/blood-based tests) are NOT accepted as confirmation methods per this policy — only biopsy or imaging elastography. If biopsy is used, NAS ≥ 4 with score > 1 in all three components (steatosis, hepatocyte ballooning, lobular inflammation) is required. Type I DM is excluded (investigational); Type II DM is NOT excluded but must be managed per standard of care. Alcohol limits: >20 g/day for women and >30 g/day for men within past 3 months is an exclusion. Concomitant Rezdiffra use is investigational. For contracts including obesity medication coverage, the MASH F2-F3 diagnosis requirement is an additional company requirement; for contracts excluding obesity medication coverage, absence of confirmed diagnosis results in not covered determination.

Policy effective May 1, 2026 · verified June 2, 2026 · source: 00886%2020240812%20 Wegovy%20semaglutideaccessible%20pdf

Open on its own page →

If weight loss isn't covered on your plan

BCBS Louisiana has separate Wegovy policies that don't depend on that benefit:

Questions people ask
Does BCBS Louisiana cover Wegovy?
No. BCBS Louisiana's policies on file exclude Wegovy for weight loss on Employer and ACA Marketplace plans.
How long does a Wegovy approval last with BCBS Louisiana?
Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. Initial approval: 6 months.
What does BCBS Louisiana require to renew Wegovy?
Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. For continuation: patient must have established CVD (same qualifying events as initial), must have had a baseline BMI ≥ 27 kg/m2 prior to therapy initiation, must not have developed Type II DM since previous authorization, must not have NYHA Class IV heart failure/chronic pancreatitis/acute pancreatitis within last 180 days, must continue GDMT, and must be tolerating maintenance dose (2.4 mg/week for injection or 25 mg/day for tablet). Age ≥ 45 is NOT re-verified at continuation. A1C exclusion (≥6.5%) is NOT explicitly re-verified at continuation (only new T2DM diagnosis is checked). Staying on a maintenance dose of at least 2.4 mg. Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. For continuation: patient must be experiencing a positive clinical response as evidenced by documentation of stabilization and/or improvement in fibrosis and/or MASH (e.g., improved steatosis, improved fibrosis, improvement in fibrosis score, lack of disease progression). Patient must not have progressed to stage F4 (cirrhosis). Patient must have been adherent to treatment. Patient must be tolerating maintenance dose of 2.4 mg once weekly. Comorbid conditions (dyslipidemia, T2DM, hypertension) must be managed per standard of care. Alcohol limits continue to apply (within past 3 months). Initial diagnosis confirmation testing (biopsy/imaging) is NOT re-required at continuation — only documentation of MASH F2-F3 diagnosis is needed. Staying on a maintenance dose of at least 2.4 mg.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Louisiana: Mounjaro, Ozempic

Wegovy under other plans: Louisiana Medicaid, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska

All insurance plans · All medications

Summary of BCBS Louisiana's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.